PATENT CLAIM ANALYSIS

Application Number: 15752128
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "325000"]

Abstract:
The invention provides a series of conformationally stable kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds.

Claim (Index 14):
The method of  claim 12  wherein the cancer cells cause melanoma, breast cancer, or rhabdomyosarcoma.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 88.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10716165', '11718692', '12731089', '14488296', '14488294']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6434300120627389
- 35 USC 102 Novelty (BERT): 0.5212349983224878
- Combined Prediction Score: 0.6312105106887137
- Mean Citation Score: 207.554184
- Max Citation Score: 222.47041
- Similarity Product: 126.36081016864716

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test